GSK logo

GSK
Glaxosmithkline plc - ADR

9,515
Mkt Cap
$119.35B
Volume
3.92M
52W High
$59.62
52W Low
$32.38
PE Ratio
15.92
GSK Fundamentals
Price
$60.22
Prev Close
$59.17
Open
$59.31
50D MA
$49.57
Beta
0.26
Avg. Volume
5.18M
EPS (Annual)
$3.72
P/B
5.47
Rev/Employee
$627,308.01
Loading...
Loading...
News
all
press releases
GSK PLC Sponsored ADR (NYSE:GSK) Declares Dividend Increase - $0.49 Per Share
GSK PLC Sponsored ADR (NYSE:GSK) declared a quarterly dividend on Wednesday, February 4th. Stockholders of record on Friday, February 20th will be given a dividend of 0.4856 per share by the...
MarketBeat·1h ago
News Placeholder
More News
News Placeholder
Amazon Beats Google's Capex; Negative Sentiment Is Good; Tradable Low Points For Stocks, Gold, Silver, And Bitcoin
Sentiment Change Creates Opportunity read more...
Benzinga·2h ago
News Placeholder
GSK Gets EU Approval for Expanded Use of Nucala in COPD
GSK secures EU approval for Nucala, an add-on maintenance treatment for chronic obstructive pulmonary disease in adults.
Zacks·2h ago
News Placeholder
GSK (LON:GSK) Insider Purchases 52,850 in Stock
GSK plc (LON:GSK - Get Free Report) insider Jonathan Symonds bought 2,500 shares of GSK stock in a transaction on Thursday, February 5th. The stock was purchased at an average price of GBX 2,114 per...
MarketBeat·6h ago
News Placeholder
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of RAPT Therapeutics, Inc. (NasdaqGM: RAPT) to GSK...
Business Wire·21h ago
News Placeholder
Shore Capital Reaffirms "Buy" Rating for GSK (LON:GSK)
Shore Capital reissued a "buy" rating and set a GBX 2,300 price target on shares of GSK in a report on Wednesday...
MarketBeat·23h ago
News Placeholder
Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings?
GILD readies Q4 results as HIV drugs Biktarvy and Descovy drive growth, while Yeztugo uptake and cell therapy headwinds shape expectations.
Zacks·1d ago
News Placeholder
GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook
GSK's Q4 earnings and sales top estimates as strong specialty medicine demand fuels growth and drives shares higher on an upbeat 2026 outlook.
Zacks·2d ago
News Placeholder
GSK (GSK) Surpasses Q4 Earnings and Revenue Estimates
Glaxo (GSK) delivered earnings and revenue surprises of +6.25% and +2.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
Why GSK (GSK) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·3d ago
<
1
2
...
>

Latest GSK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.